

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**In the claims:**

Claim 1 (Currently Amended) A composition comprising two or more recombinant polypeptides having different amino acid sequences wherein the composition ~~which~~, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or more of hypervirulent lineages A4, ET-5 and lineage 3 of N.meningitidis serogroup B.

Claims 2-3 (Canceled).

Claim 4 (Currently Amended) ~~[[A]]~~ The composition of claim 1 wherein the two or more recombinant polypeptides comprise~~[[ing]]~~ five meningococcal antigens: (1) a 'NadA' protein; (2) a '741' protein; (3) a '936' protein; (4) a '953' protein; and (5) a '287' protein.

Claim 5 (Original) The composition of claim 4, wherein the NadA protein has 85% or more identity to SEQ ID 2.

Claim 6 (Original) The composition of claim 5, wherein the NadA protein comprises SEQ ID 2.

Claim 7 (Previously Presented) The composition of claim 4, wherein the 741 protein has 85% or more identity to SEQ ID 3.

Claim 8 (Original) The composition of claim 7, wherein the 741 protein comprises SEQ ID 3.

Claim 9 (Previously Presented) The composition of claim 4, wherein the 936 protein has 85% or more identity to SEQ ID 4.

Claim 10 (Original) The composition of claim 9, wherein the 936 protein comprises SEQ ID 4.

Claim 11 (Previously Presented) The composition of claims 4, wherein the 953 protein has 85% or more identity to SEQ ID 5.

Claim 12 (Original) The composition of claim 11, wherein 953 protein comprises SEQ ID 5.

Claim 13 (Previously Presented) The composition of claim 4, wherein the 287 protein has 85% or more identity to SEQ ID 6.

Claim 14 (Original) The composition of claim 13, wherein the 287 protein comprises SEQ ID 6.

Claim 15 (Previously Amended) The composition of claim 4, wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

Claim 16 (Currently Amended) The composition of claim 1, wherein the two recombinant polypeptides are expressed as ~~composition comprises a polypeptide which comprises a pair of antigens within~~ a single polypeptide chain and are selected from the group of antigens consisting of: a 'NadA' protein & a '741' protein; the 'NadA' protein & a '936' protein; the 'NadA' protein & a '953' protein; the 'NadA' protein & a '287' protein; the '741' protein & the '936' protein; the '741' protein & the '953' protein; the '741' protein & the '287' protein; the '936' protein & the '953' protein; the '936' protein & the '287' protein; the '953' protein & the '287' protein.

Claim 17 (Currently Amended) The composition of claims 15 or 16 ~~[[1]]~~, wherein the single polypeptide chain ~~composition~~ comprises a polypeptide of formula  $\text{NH}_2\text{-A-X}_1\text{-L-X}_2\text{[-X-L]}_n\text{-B-COOH}$ , wherein: X<sub>1</sub> is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the '741' protein; the '936' protein; the '953' protein; and the '287' protein ~~(1) to (5)~~; X<sub>2</sub> is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the '741' protein; the '936' protein; the '953' protein; and the '287' protein provided that X<sub>1</sub> is not the same as X<sub>2</sub>; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence; ~~and~~ n is 2, 3, 4, or 5.

Claim 18 (Currently Amended) The composition of claim 17, wherein ~~n is 2~~, X<sub>1</sub> is the ~~the~~ 936 protein and X<sub>2</sub> is the ~~the~~ 741 protein.

Claim 19 (Currently Amended) The composition of claim 17, wherein ~~n is 2~~, X<sub>1</sub> is the ~~the~~ 287 protein and X<sub>2</sub> is the ~~the~~ 953 protein.

Claims 20-21 (Canceled).

Claim 22 (Currently Amended) The composition of claim 4[[1]], further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Currently Amended) The composition of claim 4[[1]], further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Previously Presented) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM<sub>197</sub> or *H.influenzae* protein D.

Claim 25 (Currently Amended) The composition of claim 4[[1]], further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Currently Amended) The composition of ~~any one of~~ claims 1 or 4 further comprising a pharmaceutically acceptable carrier, for use as a medicament.

Claim 27 (Canceled).

Claim 28 (Currently Amended) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 1, [[or]] 4, 15, or 16.

Claims 29-31 (Canceled).